PL342500A1 - Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists - Google Patents

Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists

Info

Publication number
PL342500A1
PL342500A1 PL98342500A PL34250098A PL342500A1 PL 342500 A1 PL342500 A1 PL 342500A1 PL 98342500 A PL98342500 A PL 98342500A PL 34250098 A PL34250098 A PL 34250098A PL 342500 A1 PL342500 A1 PL 342500A1
Authority
PL
Poland
Prior art keywords
pyrolydin
derivatives
application
carboxylic acid
endothelin antagonists
Prior art date
Application number
PL98342500A
Other languages
English (en)
Inventor
Martin Winn
Steven A Boyd
Charles W Hutchins
Hwan-Soo Jae
Andrew S Tasker
Thomas W Von Geldern
Jeffrey A Kester
Bryan K Sorensen
Bruce G Szczepankiewicz
Kenneth J Henry
Gang Liu
Steven J Wittenberger
Steven A King
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/905,913 external-priority patent/US6162927A/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PL342500A1 publication Critical patent/PL342500A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL98342500A 1997-08-04 1998-07-27 Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists PL342500A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/905,913 US6162927A (en) 1994-08-19 1997-08-04 Endothelin antagonists
US4895598A 1998-03-27 1998-03-27
PCT/US1998/015479 WO1999006397A2 (en) 1997-08-04 1998-07-27 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists

Publications (1)

Publication Number Publication Date
PL342500A1 true PL342500A1 (en) 2001-06-04

Family

ID=26726720

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98342500A PL342500A1 (en) 1997-08-04 1998-07-27 Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists

Country Status (16)

Country Link
EP (1) EP1003740A2 (tr)
JP (1) JP2001512119A (tr)
CN (1) CN1301264A (tr)
AU (1) AU748469B2 (tr)
BG (1) BG104216A (tr)
BR (1) BR9815296A (tr)
CA (1) CA2297894A1 (tr)
HU (1) HUP0003484A3 (tr)
IL (1) IL134175A0 (tr)
NO (1) NO20000542L (tr)
NZ (1) NZ502395A (tr)
PL (1) PL342500A1 (tr)
SK (1) SK1452000A3 (tr)
TR (4) TR200501137T2 (tr)
TW (1) TW552260B (tr)
WO (1) WO1999006397A2 (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337230A1 (en) * 1998-07-15 2000-01-27 Bristol-Myers Squibb Company Stereoselective reductive amination of ketones
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
CA2433090A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
PE20021032A1 (es) * 2001-04-11 2002-11-12 Abbott Lab Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
WO2007034406A1 (en) * 2005-09-22 2007-03-29 Actelion Pharmaceuticals Ltd Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin
US20090054473A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
EP2961735B1 (en) 2013-02-28 2017-09-27 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
US9758495B2 (en) 2013-03-14 2017-09-12 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
CN104262329A (zh) * 2014-10-22 2015-01-07 南京友杰医药科技有限公司 反式阿曲生坦的制备
WO2024022262A1 (zh) * 2022-07-25 2024-02-01 深圳信立泰药业股份有限公司 一种内皮素a(eta)受体拮抗剂化合物的盐及其制备方法和医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
ATE219077T1 (de) * 1994-08-19 2002-06-15 Abbott Lab Endothelin antagoniste
BR9707394A (pt) * 1996-02-13 1999-04-06 Abbott Lab Derivados de ácido 4-(benzo-1,3-dioxolil) pirrolidino-3-carboxílico como antagonistas endotelina
US5618949A (en) * 1996-07-12 1997-04-08 Abbott Laboratories Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds

Also Published As

Publication number Publication date
WO1999006397A2 (en) 1999-02-11
NO20000542D0 (no) 2000-02-02
WO1999006397A3 (en) 1999-12-09
TR200501137T2 (tr) 2005-12-21
TW552260B (en) 2003-09-11
NO20000542L (no) 2000-04-04
IL134175A0 (en) 2001-04-30
NZ502395A (en) 2002-08-28
TR200101234T2 (tr) 2002-06-21
JP2001512119A (ja) 2001-08-21
TR200101233T2 (tr) 2002-06-21
HUP0003484A3 (en) 2002-02-28
CA2297894A1 (en) 1999-02-11
SK1452000A3 (en) 2001-05-10
CN1301264A (zh) 2001-06-27
AU8592198A (en) 1999-02-22
HUP0003484A2 (hu) 2002-01-28
BR9815296A (pt) 2001-11-20
AU748469B2 (en) 2002-06-06
TR200000993T2 (tr) 2000-12-21
BG104216A (bg) 2000-12-29
EP1003740A2 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
HK1005801A1 (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
PL337698A1 (en) Derivatives of 4-bromo- or iodo-phenylaminobenzhydroxamic acid and their application as mek inhibitors
PL337781A1 (en) Antagonists and reverse antagonists of glucogene
EP1024130A4 (en) BIPHENYL-5-ALKANIC ACID DERIVATIVES AND THEIR USE
HUP0100178A3 (en) Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
SI1371647T1 (en) Pyridine-3-carboxylic acid derivatives and their use as intermediates
PL342500A1 (en) Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists
HUP0003761A3 (en) Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
PL340589A1 (en) Derivatives of thienepyrimidine and thienepyridine useful as anticarcinogenic agents
ZA989505B (en) Substituted isoquinoline-3-carboxamides their preparation and their use as pharmaceuticals
PL339053A1 (en) Novel derivatives of 2-oxy-pyrimidyn-4-one and pyrimidin-4-thione as fungicides
AU1307299A (en) Stable pharmaceutical compositions including ascorbic acid and methods of using same
IL135177A0 (en) Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same
PL337645A1 (en) Novel amidine derivatives and their application as thrombosin inhibitors
IL129089A0 (en) New derivatives from piperidine-keto acid their preparation and use
IL131756A0 (en) Substituted isoquinoline derivatives and their use as anticonvulsants
PL340461A1 (en) Derivatives of isothiazocarboxylic acid
PL341221A1 (en) Derivatives of phenylaminoalkyl carboxylic acid and pharmacological compositions containing them
PL330642A1 (en) Substituted derivatives of pyrazolyl-pyrazoles and their application as herbicides
AU2456701A (en) Pharmaceutical and veterinary uses of endothelin antagonists
PL341222A1 (en) Substitute derivatives of isoquinoline and their application as anticonvulsants
HK1020944A1 (en) Substituted heterocyclic benzocycloalkenes and their use as analgesically active compounds
AU1522400A (en) Substituted pyrimidine compositions and methods of use
IL133104A0 (en) New - beta-amino and beta-azidocarboxylic acid derivatives the production thereof and the use thereof as endothelin receptor antagonists
AU6120298A (en) 2-peperazinone-1-acetic acid derivatives and their use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)